NCT03763643 is a EARLY_PHASE1 clinical trial of Rituximab in Focal Segmental Glomerulosclerosis, sponsored by University of Minnesota.

Who is sponsoring NCT03763643?

NCT03763643 is sponsored by University of Minnesota.

What drugs are being tested in NCT03763643?

Interventions in NCT03763643: Rituximab, Plasmapheresis.

What condition does NCT03763643 study?

NCT03763643 studies Focal Segmental Glomerulosclerosis.

Is NCT03763643 still recruiting?

NCT03763643 is currently completed. Last updated 10 September 2025.

Last reviewed 2025-09-10 · How we verify

NCT03763643

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

Completed EARLY_PHASE1 Last updated 10 September 2025

What this trial tests

EARLY_PHASE1 trial testing Rituximab in Focal Segmental Glomerulosclerosis in 21 participants. Completed in 7 February 2025.

Timeline

1 July 2019

Primary endpoint
7 February 2025

7 February 2025

Quick facts

Lead sponsor	University of Minnesota
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	21
Start date	1 July 2019
Primary completion	7 February 2025
Estimated completion	7 February 2025
Sites	12 locations across United States

Drugs / interventions tested

Rituximab — full drug profile →
Plasmapheresis — full drug profile →

Conditions studied

Focal Segmental Glomerulosclerosis — all drugs for Focal Segmental Glomerulosclerosis →

Sponsor

University of Minnesota

Who can join

Adults 1 to 65, any sex, with Focal Segmental Glomerulosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot/feasibility, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to or at the time of kidney transplantation can prevent recurrent FSGS in children and adults.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Recurrent Glomerular Disease after Kidney Transplantation: Diagnostic and Management Dilemmas.
Uffing A, Hullekes F, Riella LV, Hogan JJ. · · 2021 · cited 43× · PMID 34686531 · DOI 10.2215/cjn.00280121
Rituximab or plasmapheresis for prevention of recurrent focal segmental glomerulosclerosis after kidney transplantation: A systematic review and meta-analysis.
Boonpheng B, Hansrivijit P, Thongprayoon C, Mao SA, et al · · 2021 · cited 18× · PMID 34316454 · DOI 10.5500/wjt.v11.i7.303
A randomized controlled trial of preemptive rituximab to prevent recurrent focal segmental glomerulosclerosis post-kidney transplant (PRI-VENT FSGS): protocol and study design.
Rheault MN, Amaral S, Bock M, Chambers ET, et al · · 2023 · cited 7× · PMID 37675355 · DOI 10.3389/fneph.2023.1181076
Advances in Focal Segmental Glomerulosclerosis Treatment From the Perspective of the Newest Mechanisms of Podocyte Injury.
Zhu Y, Xu G. · · 2025 · cited 2× · PMID 39935575 · DOI 10.2147/dddt.s498457
Post-transplant glomerular diseases: update on pathophysiology, risk factors and management strategies.
Regalia A, Abinti M, Alfieri CM, Campise M, et al · · 2024 · cited 1× · PMID 39664990 · DOI 10.1093/ckj/sfae320
Recurrence of focal segmental glomerulosclerosis: An updated review of pathophysiology, biomarkers, and therapeutic strategies.
Oatley Z, Jaber D, Rayarakula N, Guirguis T, et al · · 2026 · PMID 41906863 · DOI 10.1177/09636897261417049

Verify or expand the search:

Other trials of Rituximab

Trials testing the same drug.

NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT06965114 — Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia · Phase 1, PHASE2 · recruiting
NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting

Other recruiting trials for Focal Segmental Glomerulosclerosis

Currently open trials in the same condition.

NCT06664814 — An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomeruloscleros · Phase 2 · recruiting
NCT07220083 — A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosc · Phase 3 · recruiting
NCT06500702 — A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Ye · Phase 2 · recruiting
NCT05942625 — A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects · Phase 1 · recruiting
NCT05588063 — taVNS for FRNS in Children · NA · recruiting

Other University of Minnesota trials

Trials by the same sponsor.

NCT02421497 — MRI Technical Development and Applications in Kidney Disease · not yet recruiting
NCT04100109 — Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic · NA · withdrawn
NCT05454306 — Anser Clavicle Pin for Surgical Management of Midshaft Clavicle Fractures · NA · withdrawn
NCT03192007 — Multi-Parametric MRI for Renal Transplantation · not yet recruiting
NCT04940533 — Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03763643 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Minnesota
Last refreshed: 10 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03763643.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing